Amorphous C66 Solid Dispersion for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Curcumin derivative C66 exhibits poor water solubility and low oral bioavailability, limiting its effectiveness as a therapeutic drug for kidney diseases and other conditions.
Innovation Solution
A solid dispersion of curcumin derivative C66 is prepared using carrier materials like polyethylene glycol 6000, povidone K30, copovidone S630, and hydroxypropyl methylcellulose acetate succinate, dispersed in microcrystalline or amorphous forms, enhancing solubility and bioavailability through methods such as spray drying, hot-melt extrusion, or melt dispersion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin derivative C66 is used as a therapeutic drug, then therapeutic efficacy is improved, but water solubility deteriorates
Solution Approach 1:
The patent changes the physical state parameter of C66 from crystalline to amorphous form through controlled preparation methods, significantly improving water solubility while maintaining therapeutic efficacy. The amorphous form allows better dissolution in aqueous environments compared to the crystalline form.
Solution Approach 2:
The patent introduces carrier materials as intermediaries to facilitate the dissolution and absorption of C66. These carriers act as mediators that enhance the solubility and bioavailability of the curcumin derivative without compromising its therapeutic activity.
2Reliability
If curcumin derivative C66 is used as a therapeutic drug, then therapeutic efficacy is improved, but oral bioavailability deteriorates
Solution Approach 1:
The patent modifies the physical parameters of C66 by creating amorphous solid dispersion, which significantly enhances oral bioavailability. The amorphous form improves dissolution rate and absorption efficiency compared to the crystalline form, thereby increasing bioavailability while preserving therapeutic efficacy.
Solution Approach 2:
The patent develops composite materials by combining C66 with specific carrier materials in amorphous form. This composite approach enhances the bioavailability of the curcumin derivative through improved dissolution and absorption characteristics while maintaining its therapeutic properties.
3Quantity of substance
If solid dispersion is prepared using conventional methods, then solubility is improved, but physical stability deteriorates
Solution Approach 1:
The patent precisely controls preparation parameters including temperature, time, and processing conditions to maintain the amorphous form of C66 in the solid dispersion. This controlled parameter adjustment ensures both high solubility and physical stability by preventing crystallization and maintaining the desired amorphous structure.
Solution Approach 2:
The patent selects and uses specific carrier materials as intermediaries that not only enhance solubility but also provide structural stability to the amorphous solid dispersion. These carriers act as stabilizing agents that prevent phase transition and maintain physical stability while facilitating improved solubility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid dispersion significantly improves water solubility and oral bioavailability of C66, ensuring stability and suitability for pharmaceutical formulations, with oral bioavailability increased by 6.66 times compared to the original form.
Implementation Method 1
a solid dispersion of curcumin derivative C66, including a curcumin derivative and a carrier material; the curcumin derivative is C66... the curcumin derivative is dispersed in the carrier material in a microcrystalline or amorphous form
Implementation Method 2
enhancing solubility and bioavailability through methods such as spray drying, hot-melt extrusion, or melt dispersion
Data Source
Figure 1~2
Figure 3
AI summary
The present invention relates to the field of pharmaceutical chemicals, and in particular, to a solid dispersion of a curcumin derivative C66, a method for preparing same, and use thereof. In the solid dispersion described by the present invention, C66 is dispersed in a carrier material in a microcrystalline or amorphous form. Compared with the C66 substance, the C66 solid dispersion features significantly improved dissolution rate of C66 in a dissolution medium. In a Beagle dog oral bioavailability study, the absolute bioavailability of the C66 solid dispersion was 6.66 times that of the C66 substance. Meanwhile, the C66 solid dispersion is good in stability, and after a 6-month acceleration study, the dissolution rate, related substances, isomers, and the like met the quality control requirements. The powder features good fluidity and good formulation processing performance. Capsules can be conveniently prepared by means of a direct powder filling process, and tablets can be prepared by means of a direct powder pressing process. This lays a foundation for further development of C66 formulation products.